Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience

BackgroundUnresectable hepatocellular carcinoma (u-HCC) still accounts for the majority of newly diagnosed HCC which with poor prognosis. In the era of systemic therapy, combination therapy with programmed cell death protein-1 (PD-1) inhibitors and tyrosine kinase inhibitors (TKIs) has become mainst...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Laihui Luo, Yongqiang Xiao, Guoqing Zhu, Aihong Huang, Shengjiang Song, Tao Wang, Xian Ge, Jin Xie, Wei Deng, Zhigao Hu, Wu Wen, Haoran Mei, Renhua Wan, Renfeng Shan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Subjects:	unresectable hepatocellular carcinoma hepatic arterial infusion chemotherapy programmed cell death protein-1 tyrosine kinase inhibitors conversion therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1004652/full